Cargando…
Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients un...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010623/ https://www.ncbi.nlm.nih.gov/pubmed/24812486 http://dx.doi.org/10.2147/OPTH.S56624 |
_version_ | 1782479883920736256 |
---|---|
author | Mushtaq, Bushra Crosby, Niall J Dimopoulos, Antonios T Lip, Peck Lin Stavrou, Panagiota El-Sherbiny, Samer Yang, Yit |
author_facet | Mushtaq, Bushra Crosby, Niall J Dimopoulos, Antonios T Lip, Peck Lin Stavrou, Panagiota El-Sherbiny, Samer Yang, Yit |
author_sort | Mushtaq, Bushra |
collection | PubMed |
description | PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients undergoing intravitreal bevacizumab therapy for DME were identified from the departmental database of a tertiary referral unit. Following the initial injection, a retreatment was performed for any persistent macular edema, unless there had been no previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT characteristics. Comparisons were made between data at baseline and 12 months after the first injection, and differences were tested for statistical significance using the Student’s t-test. RESULTS: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT >400 μm) had significantly more injections than group 1 (CRT <400 μm) (4.0 versus 3.3; P=0.003). Both groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular traction at baseline. The reduction in CRT was significantly greater in group 2 when compared to group 1 (P<0.0001). In terms of visual gain between baseline and month 12, each gained significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), but there was no difference between groups 1 and 2 (P=0.99). CONCLUSION: These results do not support a 400 μm baseline CRT cut-off for treating DME with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that patients with a thicker CRT require more bevacizumab injections, making treatment less cost-effective for these patients. Our results could be used by practitioners to support the use of bevacizumab in DME without applying a CRT cut-off. |
format | Online Article Text |
id | pubmed-4010623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40106232014-05-08 Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema Mushtaq, Bushra Crosby, Niall J Dimopoulos, Antonios T Lip, Peck Lin Stavrou, Panagiota El-Sherbiny, Samer Yang, Yit Clin Ophthalmol Original Research PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients undergoing intravitreal bevacizumab therapy for DME were identified from the departmental database of a tertiary referral unit. Following the initial injection, a retreatment was performed for any persistent macular edema, unless there had been no previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT characteristics. Comparisons were made between data at baseline and 12 months after the first injection, and differences were tested for statistical significance using the Student’s t-test. RESULTS: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT >400 μm) had significantly more injections than group 1 (CRT <400 μm) (4.0 versus 3.3; P=0.003). Both groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular traction at baseline. The reduction in CRT was significantly greater in group 2 when compared to group 1 (P<0.0001). In terms of visual gain between baseline and month 12, each gained significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), but there was no difference between groups 1 and 2 (P=0.99). CONCLUSION: These results do not support a 400 μm baseline CRT cut-off for treating DME with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that patients with a thicker CRT require more bevacizumab injections, making treatment less cost-effective for these patients. Our results could be used by practitioners to support the use of bevacizumab in DME without applying a CRT cut-off. Dove Medical Press 2014-04-28 /pmc/articles/PMC4010623/ /pubmed/24812486 http://dx.doi.org/10.2147/OPTH.S56624 Text en © 2014 Mushtaq et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Mushtaq, Bushra Crosby, Niall J Dimopoulos, Antonios T Lip, Peck Lin Stavrou, Panagiota El-Sherbiny, Samer Yang, Yit Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title_full | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title_fullStr | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title_full_unstemmed | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title_short | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
title_sort | effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010623/ https://www.ncbi.nlm.nih.gov/pubmed/24812486 http://dx.doi.org/10.2147/OPTH.S56624 |
work_keys_str_mv | AT mushtaqbushra effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT crosbyniallj effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT dimopoulosantoniost effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT lippecklin effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT stavroupanagiota effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT elsherbinysamer effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema AT yangyit effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema |